The neuroscience community at UB is very diverse. There are a lot of faculty in the medical school, but also faculty in biology and psychology, as well as exercise science and elsewhere, says Fraser J. Sim, PhD, associate professor of pharmacology and toxicology and director of the neuroscience program.

We really encompass everything from very basic science relating to brain function, all the way up to translational disease-focused research. Neuroscience covers the study of single molecules to entire behaving organisms and it is great to have one day to bring everyone together to present and share their data.

It is a great opportunity for our students to present their research, especially masters students who are only in the program for two years. They routinely do not go to many national and international meetings just because of the short period of time in the masters program and its hard for them to get enough data to present, Sim adds.

It also gives them a chance to see how research is disseminated. We have an excellent external speaker come in from outside of Buffalo, as well as presentations by local faculty. We also provide an opportunity for senior doctoral students and postdoctoral fellows to give a talk to better prepare them for the future.

Elizabeth G. Mietlicki-Baase, PhD, assistant professor of exercise and nutrition sciences in the School of Public Health and Health Professions (SPHHP), is president of the Buffalo Chapter of SfN.

Neuroscience Research Day is an excellent opportunity for local neuroscientists to discuss ongoing research and potential future collaborations, she says. I think our event is particularly beneficial for trainees as they get the opportunity to present their work to researchers with diverse scientific interests.

The following postdoctoral and doctoral students won awards:

Best Short-Talk Presentation

Best Poster Presentations

The following list includes the other oral presentations, including title, authors and faculty mentors:

The following list includes the other poster presentations, including title, authors and faculty mentors:

Catherine M. Kotz, PhD, professor and director of graduate studies in the Department of Integrative Biology and Physiology at the University of Minnesota,gave a distinguished scientist lecture.

The title of her presentation was Targeting Brain Orexin to Mitigate Obesity and Cognitive Impairment.

A new faculty member talk was also given by Soo-Kyung Lee, PhD, Empire Innovation Professor and Om P. Bahl Endowed Professor of biological sciences in the College of Arts and Sciences (CAS).

Institutional support for the event was provided by the neuroscience program and departments of Pharmacology and Toxicologyand Neurology in the Jacobs School of Medicine and Biomedical Sciences; the Department of Exercise and Nutrition Sciences in the SPHHP; and the departments of Biological Sciences and Psychiatry, and the Center for Ingestive Behavior Research in the CAS. Additional support was provided by the Society for Neuroscience.

The event was conductedOct. 11 at the Center for the Arts on UBs North Campus.

See the original post:
Neuroscience Research Day Hosts 67 Presentations - Jacobs School of Medicine and Biomedical Sciences News

Fake news is a relatively new term, yet its now seen as one of the greatest threats to democracy and free debate. In the Netflix documentary The Great Hack which chronicled the rise and fall of Cambridge Analytica we saw how Facebook data was used to target potential voters with insidious right-wing propaganda packaged as if it were news.

But how does fake news work? Neuroscience can provide at least some insight.

The first job of fake news is to catch our attention, and for this reason, novelty is key. Psychologists Gordon Pennycook and David Rand suggested that one of the reasons hyperpartisan claims are so successful is that they tend to be outlandish.

In a world full of surprises, humans have developed an exquisite ability to rapidly detect and orient towards unexpected information or events. Novelty is an essential concept underlying the neural basis of behavior, and plays a role at nearly all stages of neural processing.

Sensory neuroscience has shown that only unexpected information can filter through to higher stages of processing. The sensory cortex may have therefore evolved to adapt to, to predict, and to quiet down the expected regularities of our experiences, focusing on events that are unpredictable or surprising. Neural responses gradually reduce each time we are exposed to the same information, as the brain learns that this stimulus has no reward associated with it.

Novelty itself is related to motivation. Dopamine, a neurotransmitter associated with reward anticipation, increases when we are confronted by novelty. When we see something new, we recognize its potential for rewarding us in some way. Further studies show that the ability of the hippocampus to create new synaptic connections between neurons (a process known as plasticity) is increased by the influence of novelty. By increasing the plasticity of the brain, the potential for learning new concepts is increased.

The primary region involved in responding to novel stimuli the substantia nigra/ventral segmental area or SN/VTA is closely linked to the hippocampus and the amygdala, both of which play important roles in learning and memory. While the hippocampus compares stimuli against existing memories, the amygdala responds to emotional stimuli and strengthens associated long-term memories.

This aspect of learning and memory formation is of particular interest to my own lab, where we study brain oscillations involved in long-term memory consolidation. This process occurs during sleep, a somewhat limited time frame to integrate all of our daily information. For this reason, the brain is adapted to prioritise certain types of information. Highly emotionally provocative information stands a stronger chance of lingering in our minds and being incorporated into long-term memory banks.

The allure of fake news is therefore reinforced by its relationship to memory formation. A recent study, published in Psychological Science, highlighted that exposure to propaganda may induce false memories. In one of the largest false-memory experiments to date, scientists gathered up registered voters in the Republic of Ireland in the week preceding the 2018 abortion referendum.

Half of the participants reported a false memory for at least one fabricated event, with more than one third of participants reporting a specific, eye-witness memory. In-depth analysis revealed that voters were most susceptible to forming false memories for fake news that closely aligned with their beliefs, particularly if they had low cognitive ability.

The ability of fake news to grab our attention and then highjack our learning and memory circuitry goes a long way to explaining its success. But its strongest selling point is its ability to appeal to our emotions. Studies of online networks show text spreads more virally when it contains a high degree of moral emotion, which drives everything we do.

Decisions are often driven by deep-seated emotion that can be difficult to identify. In the process of making a judgment, people consult or refer to an emotion catalogue carrying all the positive and negative tags consciously or unconsciously associated with a given context.

We rely on our ability to place information into an emotional frame of reference that combines facts with feelings. Our positive or negative feelings about people, things and ideas arise much more rapidly than our conscious thoughts, long before were aware of them. This processing operates with exposures to emotional content as short as 1/250th of a second, an interval so brief that there is no recognition or recall of the stimulus.

Merely being exposed to a fake news headline can increase later belief in that headline, so scrolling through social media feeds laden with emotionally provocative content has the power to change the way we see the world and make political decisions.

Read more: How fake news gets into our minds, and what you can do to resist it

The novelty and emotional conviction of fake news, and the way these properties interact with the framework of our memories, exceeds our brains analytical capabilities. Though its impossible to imagine a democratic structure without disagreement, no constitutional settlement can function if everything is a value judgement based on misinformation.

In the absence of any authoritative perspective on reality, we are doomed to navigate our identities and political beliefs at the mercy of our brains more basal functions. The capacity to nurture and sustain peaceful disagreement is a positive characteristic of a truly democratic political system.

But before democratic politics can begin, we must be able to distinguish between opinions and facts, fake news and objective truth.

[ Deep knowledge, daily. Sign up for The Conversations newsletter. ]

Visit link:
Fake news grabs our attention, produces false memories and appeals to our emotions - The Conversation CA

SAN FRANCISCO, Nov. 14, 2019 /PRNewswire/ -- A new theory on the source of consciousness has been published. It proposes that consciousness is an intrinsic feature of magnetic fields. Feedback between consciousness and perception is an essential feature of all experience. The human brain contains 5 million organically-formed magnetite crystals per gram. Each of these has a north and south pole, serving as in/out information channels, the basis for awareness. The brain's magnetic fields are extremely complex, and capable of supporting vast feedback mechanisms. They broadcast their information throughout the brain at a fraction of the speed of light, unifying conscious experience.

The brain experiences its own activity through its magnetism, and subjective experiences are actually the brain's magnetic field, resonating with the brain's electrical activity.

Consciousness is how magnetic each pole of a magnetic field experiences the other. Both the earth, with its geomagnetic field, and ordinary magnets, with just two poles, are conscious, but in such a rudimentary way that no one could imagine what they might experience.

Invoking the basic laws for electricity and magnetism ("Maxwell's Equations"), Prof. Todd Murphy points out that electrical currents (including the ones that run through brain cells), create magnetism, which influence the brain's magnetic fields. Its conscious magnetic field(s) "pick up," or resonate with, the brain's electrical activity, receiving its information and making organisms conscious of both mind and body. The brain may choose what to be aware of according to the information in its ongoing electrical signals and magnetic fields, possibly through specific signals that appear in response to potentially important events, especially threats and opportunities.

Prof. Todd Murphy, associated with Laurentian University's Neuroscience Program since 1998, also proposes that simple magnetic fields, from fewer magnets, support simple consciousness, such as in invertebrates with rudimentary senses (like an eye that only detects light or darkness). More complex consciousness, like that of humans or other primates, would require more developed nervous systems, and much larger numbers of magnetite crystals. Their greater nuances of thought and emotion give humans more to be aware of.

It will be a challenge to prove absolutely, because science can't prove that anything is conscious. The only way to know consciousness exists is through subjective experiences, which aren't admissible as scientific evidence. However, Murphy proposes several tests that would tend to support his theory.

Murphy's paper, "Solving the "Hard Problem":Consciousness as an Intrinsic Property of Magnetic Fields" appears in the Journal of Consciousness Exploration and Research. He's also published several journal articles, and three books in neuroscience.

Todd Murphy can be contacted at: 229184@email4pr.com or (415) 368-3667His author page can be seen here:https://tinyurl.com/murphy-todd

End.Kirschivink, Joseph L., (et al.). "Magnetite biomineralization in the Human Brain", Proceedings of the National Academy of Science 1992, 89 7683-7687

Murphy, Todd "Solving the "Hard Problem": Consciousness as an Intrinsic Property of Magnetic Fields" Journal of Consciousness Exploration & Research, 2019, 10(8) p. 800-813Link: https://jcer.com/index.php/jcj/article/view/835/850

SOURCE Todd Murphy

Originally posted here:
Neuroscience Researcher Todd Murphy Says: Consciousness is the Subjective Experience of the Brain's Magnetic Fields - PRNewswire

West Virginia University researchers are exploring whether deep brain stimulation can help patients with opioid use disorder who haven't responded to other types of treatment.

The clinical trial the first of its kind in the United States comes as opioid addiction remains a major health crisis throughout the U.S.

About 130 Americans die each day from an opioid overdose, according to theU.S. Centers for Disease Control and Prevention. In 2017, about 19.7 million American adults had a substance use disorder, the National Survey on Drug Use and Healthreported.

Unfortunately, current treatment plans are not always effective. But the trial, led by Dr. Ali Rezai, executive chair of the WVU Rockefeller Neuroscience Institute and funded by the National Institute on Drug Abuse, offers some hope.

Rezai and his research team have implanted a Medtronic DBS device in the trial's first participant, a 33-year-old man with a history of opioid and benzodiazepine use.

The DBS device, similar to a cardiac pacemaker, uses tiny electrodes to regulate certain areas of the brain. It is inserted into the brain's reward centers.

The U.S. Food and Drug Administration already has approved it for the treatment of Parkinson's disease, essential tremor dystonia, epilepsy, and obsessive-compulsive disorder. But Rezai believes it may help people battling addiction, too.

"Our team at the [Rockefeller Neuroscience Institute] is working hard to find solutions to help those affected by addiction," Dr. Rezai said in a press release."Addiction is a brain disease involving the reward centers in the brain, and we need to explore new technology, such as the use of DBS to help those severely impacted by opioid use disorder."

This first phase of the clinical trial includes four participants with opioid use disorder. All of them have tried and failed the standard of care for addiction recovery at WVU Medicine.

"Despite our best efforts using current evidence-based treatment modalities, there exist a number of patients who simply don't respond," said Dr. James Berry,interim chair of the WVU Department of Behavioral Medicine and Psychiatry and director of addiction services at the Rockefeller Neuroscience Institute."Some of these patients remain at very high risk for ongoing catastrophic health problems and even death. DBS could prove to be a valuable tool in our fight to keep people alive and well."

The trend of surgically implanting machines into humans, especially the brain, raises ethical concerns for some in scientific communities.

Rezai told BBC News that this technology is not for consumer use.

"I think it is very good for science and we need more science to advance the field and learn more about the brain," he said. "This is not for augmenting humans and that is very important. This is not consumer technology."

He added, "surgery has inherent risks and is not trivial. It is only for those with chronic disease who have failed all other treatments and are without hope."

View original post here:
Deep brain stimulation may offer a new tool to fight opioid addiction - PhillyVoice.com

Grand Warszawski / Shutterstock

Amgen submitted a Worker Adjustment and Retraining (WARN) filing with the Commonwealth of Massachusetts, indicating it planned to lay off 149 employees effective December 31, 2019. This comes only shortly after the company announced it was ending its neuroscience research.

According to a report in the San Fernando Valley Business Journal, the company, which has headquarters in Thousand Oaks, California, has spent the last five years increasing its presence in New England, shifting staff from California to Kendall Square in Cambridge. Some of the people being laid off have been offered relocation to other sites in North America. The Cambridge site will continue to work with a process development presence for pipeline products and next-generation technology.

The decision to exit the neuroscience space was announced in the companys third-quarter financial report. Upon careful evaluation of our pipeline and the challenges inherent in developing drugs for major neurologic diseases, weve made the decision to end our neuroscience research and early development programs with the exception of programs centered on neuro-inflammation, David Reese, the companys R&D head, said in the conference call.

Unfortunately, this makes Amgen yet another major biopharma company to exit or slim down work on neurological diseases. Others include Pfizer, Bristol-Myers Squibb, GlaxoSmithKline and AstraZeneca.

In July 2019, Amgen, Novartis and the Banner Alzheimers Institute announced they were halting two pivotal Phase II/III clinical trials in the Alzheimers Prevention Initiative Generation Program. The studies were evaluating the BACE1 inhibitor umibecestat (CNP520). An analysis of unblinded data during a scheduled review showed that the patients were getting worse in some of the measures of cognitive function, the opposite of what they were hoping. The three organizations jointly decided that any patient benefit wasnt worth the risk.

The Amgen and Novartis Neuroscience Collaboration launched in August 2015 to develop and market treatments for migraine and Alzheimers disease. Amgen and Novartis sponsor the work in collaboration with Banner Alzheimers Institute. Novartis is the regulatory sponsor and Amgen and Novartis are co-development partners.

Beta-amyloid is a protein that accumulates in the brains of Alzheimers patients, and was long thought to be the cause of the memory and cognitive issues in the disease. However, much of the science has moved away from that theory as dozens of clinical trials that successfully cleared or halted the production of beta-amyloid failed to make a difference in the patients clinical conditions. It is likely that beta-amyloid is still a significant player in the disease, perhaps related to neuroinflammation, but many researchers have moved away from a direct focus on beta-amyloid.

BACE1 inhibitors like umibecestat block BACE1, an enzyme that helps form amyloid plaques.

Shifting resources away from neuroscience, Amgen plans to prioritize efforts on cardiovascular disease, oncology and inflammatory diseases. About 180 positions will be affected in this decision, with 149 of them in Massachusetts.

We made the difficult decision to end our research in neuroscience, which is largely based in Cambridge, Massachusetts, a company spokesperson told Biopharma Dive. We are consolidating our U.S.-based research presence primarily in Thousand Oaks and San Francisco.

The company plans to keep a hand in the field, although less directly. It has partnerships with several groups, including deCODE, a subsidiary that specializes in genetics. We believe that genetics will ultimately drive progress in this area, and well continue to work with deCODE to generate insights, company chief executive officer Bob Bradway said in the conference call.

Amgen will also continue support for its ongoing development of Aimovig (erenumab), its drug approved for migraine.

Continue reading here:
Amgen Exits Neuroscience R&D, Plans to Cut 149 Jobs in Boston Area - BioSpace

Amgen has given notice of its intent to lay off 149 people at its Cambridge, Massachusetts, operation by the end of the year. The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations in a move that would threaten around 180 jobs.

That plan became official Friday when state authorities in Massachusetts revealed Amgen had submitted a Worker Adjustment and Retraining Notification Act note. The note formally signaled Amgens intent to cut 149 employees in Cambridge loose at the end of the year. Amgen will retain an operations and process development presence in Massachusetts but is consolidating research back in California.

Amgen focused its Cambridge research site on neuroscience and hired people versed in medicinal chemistry, pharmacokinetics and drug metabolism, genetics, cell biology and and toxicology to staff it. With Amgen exiting neuroscience research, those skills are now largely surplus to requirements.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The move to exit neuroscience R&D follows the decision by Amgen and its partner Novartis to stop pivotal tests of CNP520 in Alzheimers disease. Amgen and Novartis pulled the plug on the program after an interim review linked the BACE inhibitor to a worsening of cognitive function.

While Amgen is pulling out of in-house neuroscience research, the company has plans to continue to participate in the field in some way. Amgen believes its work with deCODE positions it to understand the genetics of neurological disorders, and, while it wants to focus its internal resources elsewhere, it's keen to capitalize on these capabilities in some way.

Half the genes in the body are expressed in the brain and only the brain and we think we have some unique resources to try to capitalize on insights around that. We'll be exploring potentially different models for doing that with venture capital and perhaps academic institutions as well, Amgen CEO Bob Bradway said on a quarterly results conference call with investors late last month.

Amgens decision to exit neuroscience follows the shuttering of an Eli Lilly facility focused on the field and the spinning out of Pfizers pipeline to create Cerevel Therapeutics.

Go here to see the original:
Amgen to cut 149 staff in retreat from neuroscience R&D - FierceBiotech

16 November 2019

There has been widespread UK media coverage for a new study, published in the journal Epidemiology that haslinked air pollution nanoparticles to brain cancerfor the first time. It was found that a one-year increase in pollution exposure of 10,000 nanoparticles per cubic centimetre the approximate difference between quiet and busy city streets increased the risk of brain cancer by more than 10%. The cities studied were Toronto and Montreal

The human brain has the ability to block cancer drugs from effectively reaching cancer cells in the brain and the greatest obstacle to treating cancer is the brains natural defence mechanism, the blood-brain barrier, the collection of blood vessels that can filter out what goes in and out of the brain. When cancer cells invade the brain, the blood-brain barrier transitions into the blood-tumour barrier, and this transition still presents aroadblock for effective drug delivery howevera new road map could ease blockages to this effective drug delivery to the brain. Recently published workinOncotarget from scientists at Purdue University, Indiana, has provided the first comprehensive characterization of both the blood-brain and blood-tumour barriers in brain metastases of lung cancer, and this will serve as a road map for treatment development. The principal investigator of the Comparative Blood-Brain Barrier Laboratory at Pudue, Tiffany Lyle said Identifying when that change occurs during the transition is critical because it tells us when and where the brain vasculature prevents effective drug delivery.

Scientists obtained new compounds with potential anti-tumour effect from sea sponge, click this link to find out more about how chemists from Far Eastern Federal University's School of Natural Sciences (SNS FEFU)developed a new method to synthesise biologically active derivatives of fascaplysin a cytotoxic pigment of a sea sponge. FEFU scientists have already shown that fascaplysin derivatives stimulate the death of glioblastoma multiforme cells - the most aggressive type of brain cancer.

Click through toPhase 1 study in patients with Glioblastoma multiforme,and read details of the first abstract (an abstract is a brief summary of a research article). It is a small study of eight patients but showed that the drug ifabotuzumab is effectively delivered across the blood-tumour barrier and accumulates specifically at the tumour site in all patients treated to date with no observed normal tissue uptake Our results show that ifabotuzumab is safe and very effective at targeting the tumour, said professors Hui Gan and Andrew Scott, who led the study from the Olivia Newton-John Cancer Research Institute in Melbourne. We are also excited that there are early indications that ifabotuzumab may help to control disease growth in some patients."

News of an encouraging trial here;Positive Phase 2 Glioblastoma DataInterim results from a Phase 2 trial testing immunotherapy AV-GBM-1 in patients with glioblastoma multiforme (GBM) shows current survival is 96% at six months and 91% at twelve months with three patients followed for more than a year. Furthermore, a vast majority of patients displayed an appropriate immune response and a decrease of tumour biomarkers. The trial is still in progress and will continue to enrol patients for a few more months with follow up for at least another year. Final analysis likely will occur in early 2021.

To learn about the difference between Phase 1 and Phase 2 clinical trials and more about the whole vital area of clinical trials please do click through to ourclinical trials information pagefor a concise but comprehensive overview.

Related stories:

More:
Weekly pick of Neuroscience news from around the world - Brain Tumour Research

Take a moment and think about how well the team at your firm works together. Chances are, there are likely more than a few ways everyone could work together more effectively. But what exactly are the drivers behind this goal of performance-driven firm leaders everywhere?

The answers might surprise you, says Abbie Louie. She's a leadership expert who went from working with Boeing to helping team leaders use neuroscience to enhance productivity at work. She beganher talk at this year's QB Connect in San Jose by referencing Project Aristotle.

In case you've never heard of it, some background: Google keeps data on everything, including the inner workings of their own organization. Over the years, they've tried a couple of unique ways to improve their company. Some have been more successful than others: One measure that involved removing managers, for instance, was quickly reversed after just a couple of months.

This new project looked into exactly what drove effective teams, and the results were, to say the least, surprising. However, they were also incredibly useful. First, they revealed that it's not really who's on the team; rather, it's how the team works together. Louie also noted Google came up with five specific drivers: impact, meaning, structure and clarity, dependability, and, the most important: psychological safety.

What exactly is that? Well, it's pretty simple, says Louie. People want to come to work in a place where they feel mentally safe and accepted. They want to feel like they can show both their strengths and their flaws, ask questions when they need to, and feel relaxed.

So, how healthy is your firm? Is it one where employees generate and voice ideas often, or are they relatively quiet and fearful of criticism? Louie says it's wise to do inventory of what's going on, since employees who are not in a psychologically safe workplace are less likely to be able to be creative and productive. There's a biological reason for this, she adds: The brain actually shuts down when it's in "fight or flight" mode.

You know your firm better than anyone else. Take stock of what's going on, and don't be afraid to make changes to enhance psychological safety.

Read more:
The Neuroscience Behind Effective Teams - Accountingweb.com

Sandy and Joan Weill Give $106 Million to Fund Neuroscience Hub  Bloomberg

Continued here:
Sandy and Joan Weill Give $106 Million to Fund Neuroscience Hub - Bloomberg

SAN DIEGO & BELFAST, Northern Ireland--(BUSINESS WIRE)--Neurovalens, a global HealthTech company focused on developing innovative neuroscience-powered products to improve lives, today introduces Modius SLEEP. The device follows the success of the Companys first headset, Modius SLIM, which raised $2.5M on Indiegogo in 2017, gaining worldwide popularity with orders from 80+ countries.

Modius SLEEP continues the Companys mission to improve global health and wellness by providing drug-free, neurological solutions for common health problems. Modius SLEEP is available for $249 for the duration of the campaign on Indiegogo and will retail for $499. Campaign Link: https://igg.me/at/modiussleep.

Thousands of Modius SLIM device users around the world found improved sleep was a welcomed bonus reaction and our motivation for making changes to our technology to create Modius SLEEP, said Jason McKeown, CEO of Neurovalens. This new headset taps into the power of the brains hypothalamus, which acts as a mini-computer and influences many areas of the brain, including weight loss and sleep. Our aim is to help people avoid sedatives and sleeping pills as they mask the underlying problem and produce unpleasant side effects. We use neuroscience to improve lives through safe, innovative, non-invasive products and have complete confidence our SLEEP device is just as life-changing as our SLIM device has been.

In a 30-day study, 95% of Modius SLEEP users improved their overall sleep score, with 85% claiming they were satisfied with their improved sleep patterns. Additionally, 71.3% with sleep issues reported positive changes when using Modius SLEEP.

How it Works:

Unlike other sleep headsets that are limited to passively reading brain-wave activity, Modius SLEEP actively stimulates the key sleep neurons in the brain, reducing time it takes to fall asleep and keeping you asleep longer. The Modius SLEEP headset is worn for 30 minutes before bed with no need to wear in bed. It works by sending a safe electrical pulse into the vestibular nerve that influences the areas of the hypothalamus and brain stem that controls the users circadian rhythm and sleep patterns.

About Neurovalens:

Neurovalens is a global healthtech company and leader in the development of non-invasive neurostimulation products which aims to improve global health and wellness using drug-free neurological solutions. Its premier product, Modius SLIM has been sold in 80+ countries and helps people meet their weight loss goals. The Modius SLEEP headset was designed to help people fix their sleep problems for good. Founded by Dr. Jason McKeown in 2015, the Company is currently run from dual-headquarters in Belfast, Northern Ireland and at the University of California San Diegos Centre for Brain & Cognition. For more information visit: https://us.modiushealth.com/pages/modius-sleep

Read more from the original source:
Neurovalens Unveils Modius SLEEP, a Genius Next-Gen Device Powered by Neuroscience to Optimize Sleep Health and Address the Global Sleep Crisis,...